BRPI0408226A - sal cristalino de cloridrato de maleato de s-[2-[(1-iminoetil)amino]etil-2-metil-l-cisteìna - Google Patents

sal cristalino de cloridrato de maleato de s-[2-[(1-iminoetil)amino]etil-2-metil-l-cisteìna

Info

Publication number
BRPI0408226A
BRPI0408226A BRPI0408226-5A BRPI0408226A BRPI0408226A BR PI0408226 A BRPI0408226 A BR PI0408226A BR PI0408226 A BRPI0408226 A BR PI0408226A BR PI0408226 A BRPI0408226 A BR PI0408226A
Authority
BR
Brazil
Prior art keywords
methyl
iminoethyl
aminoethyl
maleate hydrochloride
cysteine
Prior art date
Application number
BRPI0408226-5A
Other languages
English (en)
Inventor
Ahmad Sheikh
Lyle R Brostom
Ann M Czyzewski
Vahid Zia
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0408226A publication Critical patent/BRPI0408226A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/26—Separation; Purification; Stabilisation; Use of additives
    • C07C319/28—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

"SAL CRISTALINO DE CLORIDRATO DE MALEATO DE S-¢2-¢(1-IMINOETIL)AMINO!ETIL-2-METIL-L-CISTEìNA". é apresentada um novo sal misto de S-¢2-¢(l-iminoetil)aminoetil!2-metii-L-cisteína. O novo sal misto, cloridrato de maleato de S-¢2-¢(1iminoetil)aminoetil!-2-metil-L-cisteína pode ser preparado para formar cristais que podem ser arranjados geralmente como aglomerados empacotados ordenadamente, os quais são particularmente úteis na preparação de composições farmacêuticas. Tais composições farmacêuticas são também descritas, bem como os métodos para preparar cloridrato de maleato de S-¢2-¢(1iminoetil)aminoetil!-2-metil-L-cisteína cristalino e métodos de tratar condições caracterizadas por uma sobre expressão em óxido nítrico da isoforma induzida da óxido nítrico sintase utilizando o cloridrato de maleato de S-¢2-¢(1iminoetil)aminoetil!-2-metil-L-cisteína.
BRPI0408226-5A 2003-03-11 2004-03-04 sal cristalino de cloridrato de maleato de s-[2-[(1-iminoetil)amino]etil-2-metil-l-cisteìna BRPI0408226A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45349603P 2003-03-11 2003-03-11
PCT/IB2004/000678 WO2004080956A1 (en) 2003-03-11 2004-03-04 S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt

Publications (1)

Publication Number Publication Date
BRPI0408226A true BRPI0408226A (pt) 2006-03-01

Family

ID=32990778

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408226-5A BRPI0408226A (pt) 2003-03-11 2004-03-04 sal cristalino de cloridrato de maleato de s-[2-[(1-iminoetil)amino]etil-2-metil-l-cisteìna

Country Status (33)

Country Link
US (2) US20050038120A1 (pt)
EP (1) EP1603872B1 (pt)
JP (1) JP4794433B2 (pt)
KR (2) KR20090048521A (pt)
CN (1) CN100460387C (pt)
AR (1) AR043521A1 (pt)
AT (1) ATE509909T1 (pt)
AU (1) AU2004220266B2 (pt)
BR (1) BRPI0408226A (pt)
CA (1) CA2518745C (pt)
CL (1) CL2004000472A1 (pt)
CO (1) CO5611122A2 (pt)
CY (1) CY1112461T1 (pt)
DK (1) DK1603872T3 (pt)
ES (1) ES2363001T3 (pt)
GT (1) GT200400040A (pt)
HK (1) HK1088301A1 (pt)
IL (1) IL170554A (pt)
MX (1) MXPA05008674A (pt)
NL (1) NL1025691C2 (pt)
NO (1) NO20054645L (pt)
NZ (1) NZ574218A (pt)
PA (1) PA8597701A1 (pt)
PE (1) PE20050309A1 (pt)
PL (1) PL1603872T3 (pt)
PT (1) PT1603872E (pt)
RU (1) RU2357953C2 (pt)
SG (1) SG155782A1 (pt)
SI (1) SI1603872T1 (pt)
TW (1) TWI352076B (pt)
UY (1) UY28229A1 (pt)
WO (1) WO2004080956A1 (pt)
ZA (1) ZA200506459B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6094101A (en) * 1999-03-17 2000-07-25 Tropian, Inc. Direct digital frequency synthesis enabling spur elimination
US8015725B2 (en) * 2004-09-21 2011-09-13 Dos-I Solutions, S.L. Method and machine for the sintering and/or drying of powder materials using infrared radiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ289157A (en) * 1994-06-15 1998-03-25 Wellcome Found Amidino sulphoxides and sulphones; medicaments for selective inhibition of inducible nitric oxide synthase
ES2256223T3 (es) * 2000-03-24 2006-07-16 Pharmacia Corporation Amidinocompuestos utiles como inhibidores de oxido nitrico sintasa.
AR031608A1 (es) * 2000-09-15 2003-09-24 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR031609A1 (es) * 2000-09-15 2003-09-24 Pharmacia Corp Derivados de acido 2-amino-2-alquil-3 heptenoico y heptinoico utiles como inhibidores de oxido nitrico sintetasa

Also Published As

Publication number Publication date
CY1112461T1 (el) 2015-12-09
NZ574218A (en) 2009-11-27
NO20054645L (no) 2005-11-25
KR20050107617A (ko) 2005-11-14
CN100460387C (zh) 2009-02-11
HK1088301A1 (en) 2006-11-03
AU2004220266A1 (en) 2004-09-23
RU2357953C2 (ru) 2009-06-10
CN1787993A (zh) 2006-06-14
ES2363001T3 (es) 2011-07-18
ATE509909T1 (de) 2011-06-15
NL1025691A1 (nl) 2004-09-14
TWI352076B (en) 2011-11-11
KR20090048521A (ko) 2009-05-13
SG155782A1 (en) 2009-10-29
NO20054645D0 (no) 2005-10-10
CL2004000472A1 (es) 2005-05-13
PT1603872E (pt) 2011-06-07
MXPA05008674A (es) 2005-10-18
ZA200506459B (en) 2006-11-29
RU2005125833A (ru) 2006-05-10
PE20050309A1 (es) 2005-05-04
SI1603872T1 (sl) 2011-07-29
CA2518745A1 (en) 2004-09-23
KR100927911B1 (ko) 2009-11-19
JP4794433B2 (ja) 2011-10-19
DK1603872T3 (da) 2011-07-18
JP2006519838A (ja) 2006-08-31
PA8597701A1 (es) 2005-02-04
WO2004080956A1 (en) 2004-09-23
AU2004220266B2 (en) 2010-08-19
US7767850B2 (en) 2010-08-03
EP1603872B1 (en) 2011-05-18
PL1603872T3 (pl) 2011-09-30
CA2518745C (en) 2010-10-19
UY28229A1 (es) 2004-11-08
AR043521A1 (es) 2005-08-03
US20050038120A1 (en) 2005-02-17
NL1025691C2 (nl) 2006-06-30
EP1603872A1 (en) 2005-12-14
TW200508185A (en) 2005-03-01
US20090215891A1 (en) 2009-08-27
IL170554A (en) 2011-10-31
GT200400040A (es) 2005-01-14
CO5611122A2 (es) 2006-02-28

Similar Documents

Publication Publication Date Title
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BR0009486A (pt) Compostos que contêm uma amida, utilização desses compostos, composição farmacêutica, processo para o tratamento profilático ou terapêutico de, diabetes do tipo ii e processo para a preparação dos compostos
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
NO20085169L (no) Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
NO20073325L (no) Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
BR112013020620A2 (pt) análogos de ácido 4-hidroxibutírico
BR0213539A (pt) Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
BR0317703A (pt) Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
PE20060364A1 (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BRPI0708278B8 (pt) forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
CA2744756A1 (en) Monocarbams and their use as antibacterial agent
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them
NO983493L (no) Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike
EA200900732A1 (ru) Кристаллическая калиевая соль аналогов липоксина а
BR0015166A (pt) Naftopiranos anelados em c5 - c6, com um carbociclo do tipo indeno- ou dihidronaftaleno e composições e matrizes contendo-os
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
BRPI0411246A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para terapia contra dor em um animal de sangue quente e para a preparação de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]